Show simple item record

dc.contributor.authorO'Malley, D. M.
dc.contributor.authorOza, A. M.
dc.contributor.authorLorusso, D.
dc.contributor.authorAghajanian, C.
dc.contributor.authorOaknin, A.
dc.contributor.authorDean, A.
dc.contributor.authorColombo, N.
dc.contributor.authorWeberpals, J. I.
dc.contributor.authorClamp, Andrew R
dc.contributor.authorScambia, G.
dc.contributor.authorLeary, A.
dc.contributor.authorHolloway, R. W.
dc.contributor.authorGancedo, M. A.
dc.contributor.authorFong, P. C.
dc.contributor.authorGoh, J. C.
dc.contributor.authorArmstrong, D. K.
dc.contributor.authorBanerjee, S.
dc.contributor.authorGarcia-Donas, J.
dc.contributor.authorSwisher, E. M.
dc.contributor.authorCameron, T.
dc.contributor.authorMaloney, L.
dc.contributor.authorGoble, S.
dc.contributor.authorLin, K. K.
dc.contributor.authorLedermann, J. A.
dc.contributor.authorColeman, R. L.
dc.date.accessioned2020-12-08T05:36:33Z
dc.date.available2020-12-08T05:36:33Z
dc.date.issued2020en
dc.identifier.citationO'Malley DM, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3. Gynecologic Oncology. 2020;159:74-5.en
dc.identifier.doi10.1016/j.ygyno.2020.06.153en
dc.identifier.urihttp://hdl.handle.net/10541/623506
dc.description.abstractIn the ARIEL3 study (NCT01968213), rucaparib maintenance treatment significantlyimproved progression-free survival (PFS) versus placebo in all predefined, nestedcohorts ( BRCA mutant; BRCA mutant + wildtype BRCA/high loss of heterozygosity; and intent-to-treat population). Here we analyzed postprogressionoutcomes to evaluate the durability of the clinical benefit of rucaparib maintenancetreatment following disease progression in the subgroup of patients with tumors associatedwith a mutation in a prespecified, non- BRCA, homologous recombination repair (HRR) gene.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ygyno.2020.06.153en
dc.titlePostprogression outcomes in patients with ovarian carcinoma associated with amutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Ohio State University, James Cancer Hospital, Columbus, OH, USAen
dc.identifier.journalGynecologic Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record